FORM PTO	RM PTO-1449/A and B (modified PTO/SB/08)		1 PTO/SR/08)	APPLICATION NO.: 10/541,708	ATTY. DOCKET NO.: A0848.70010US00	
	`		,	FILING DATE: July 8, 2005	CONFIRMATION NO.: 6032	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT: Karen Silence		
Sheet	1	of	1	GROUP ART UNIT: 1644	EXAMINER: Szperka, Michael Edward	

## U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document			Date of Publication or Issue	
		Number	Kind Code	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	
	A9	6,759,518		Kontermann et al.	07-06-2004	
	A10	2002/0058033	A1	Raisch et al.	05-16-2002	
	A11	2003/0092892	A1	Frenken et al.	05-15-2003	

## FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document		nt		Date of Publication of	
		Office/ Country	Number	Kind Code	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD- YYYY	Translation (Y/N)
	B17	EP	0 952 218	A2	Hoechst Marion Roussel Deutschland GmbH	10-27-1999	

## OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C16	D'HAENS, G. et al. "Endoscopic and Histological Healing With Infliximab Anti-Tumor Necrosis	
		Factor Antibodies in Crohn's Disease: A European Multicenter Trial," Gastroenterology 1999;	
		116(5):1029-1034	
	C17	HOLLIGER, P. et al. "Retargeting serum immunoglobulin with bispecific diabodies," <i>Nature</i>	
		Biotechnology 1997 July; 15:632-636	
	C18	HOOGENBOOM, H.R. "Mix and match: Building manifold binding sites," Nature Biotechnology	
		1999 Feb.; 15:125-126	
	C19	NERI, D. et al. "High-affinity Antigen Binding by Chelating Recombinant Antibodies (CRAbs)," J.	
		Mol. Biol. 1995; 246:367-373	

<sup>#</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

<sup>\*</sup>a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_, filed \_\_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).